OUR PURPOSE PIONEERING SCIENCE ENVIRONMENT COMMUNITY REPORTING 59 BIOGEN 2021 YEAR IN REVIEW PATIENTS OUR PEOPLE OUR PEOPLE Advancing a Diverse and Inclusive Workplace Where Leading Scientific Minds Thrive EXECUTIVE SUMMARY OUR CULTURE AND EXTERNAL CONTEXT In our 2021 ESG materiality assessment, two workplace issues ranked within the top 10: employee health and safety; and talent recruitment, retention and engagement. As macro trends such as the “Great Resignation” impact an already competitive market for talent across the life sciences industry, Biogen also saw an uptick in voluntary turnover. We are responding with a program called Thrive@Biogen, designed to foster open employee relationships with managers and individualized employee engagement plans. This also incorporates feedback from employee surveys showing that our people are willing to take on increased responsibilities but would like a clearer sense of future career possibilities and to understand how their work makes a difference and fits into the bigger picture. We strive to inspire employee connection to Biogen’s purpose, even as our credo, the Biogen Elements, the Code of Business Conduct and our Ethical Principles remain the foundation of our ethical culture. These touchstones come to life in everything from our Compliance Week to annual performance reviews. Our 2021 Corporate Scorecard reflected our commitment to leadership in neuroscience, driving our biosimilars business, maximizing our robust pipeline and financial performance, as well as two new scorecard priorities: Digital Health and Environment, Social and Governance (ESG) metrics. To deliver on these goals, we foster employee engagement, with robust opportunities for growth. In 2021, we exceeded our scorecard goal for learning and development and engaged around 2,300 people across our nine Employee Resource Networks, including our new Parenting Network Group. We also sustained our employee sabbatical program, achieved record involvement in our time off to volunteer and launched a Ways of Working program to re-imagine how and where work is done. We continued to enhance our total rewards and benefits, including parental and caregiver leave and support programs, with an enhanced focus on mental health. As our world continues to wrestle with COVID-19, we have maintained safe and productive operations, prioritizing the health and well-being of our employees while ensuring delivery of our vital medicines to patients. In 2021, our Days Away Case Rate (DACR), which monitors work-related illnesses and injuries, and our Total Recordable Injury Rate (TRIR) both were largely on par with 2020. After evaluating 400 work tasks and identifying 57 critical areas that could expose employees to serious injury or fatality, we completed 82 of 92 action items by the end of 2021. We continue to advance our four-part diversity, equity and inclusion (DE&I) strategy across our workforce, for our patients and among our suppliers. In 2021, our DE&I team grew, in number and across functions; we formed an international DE&I Strategic Council and trained nearly 90% of managers on inclusive talent management practices, and 70% of employees participated in at least one DE&I workshop, training or event. We also introduced a fellowship with a historically Black college and university (HBCU) to grow our diverse talent pipeline and attract, retain and grow the world’s brightest minds. Þ LEARN MORE ABOUT OUR DE&I PROGRAMS AND PROGRESS As Biogen prepares for potential product launches, new initiatives and global geographic expansion, all of us are ambassadors for our Ethical Element. Our shared commitment to patients, healthcare professionals and the community means that we move forward with our pioneering work the right way.” Soph Sophocles Chief Compliance Officer